‪Nur Aizati Athirah Daud‬ - ‪Google Scholar‬

Get my own profile

Cited by

	All	Since 2019
Citations	161	112
h-index	6	6
i10-index	5	5

0

26

13

20152016201720182019202020212022202320246 12 19 12 21 22 22 25 15 7

Co-authors

Marian K BakkerUniversity Medical Center Groningen, Groningen, The NetherlandsVerified email at umcg.nl

Nur Aizati Athirah Daud

Nur Aizati Athirah Daud

Universiti Sains Malaysia

Verified email at usm.my

Pharmacogenetics Women Health Pharmacy Drug Use in Pregnancy and Breastfeeding Pharmacoepidemiology


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
P-glycoprotein-mediated drug interactions in pregnancy and changes in the risk of congenital anomalies: a case-reference study ANA Daud, JEH Bergman, MK Bakker, H Wang, WS Kerstjens-Frederikse, ... Drug safety 38, 651-659, 2015	53	2015
Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins ANA Daud, JEH Bergman, MK Bakker, H Wang, HEK De Walle, T Plösch, ... Pharmacogenomics 15 (7), 1029-1041, 2014	45	2014
Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies ANA Daud, JEH Bergman, MP Oktora, WS Kerstjens-Frederikse, H Groen, ... PloS one 12 (3), e0173530, 2017	23	2017
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors—Is Pharmacogenetics the Key? ANA Daud, JEH Bergman, WS Kerstjens-Frederikse, H Groen, B Wilffert International Journal of Molecular Sciences 17 (8), 1333, 2016	17	2016
Knowledge and attitude regarding pharmacogenetics among formerly pregnant women in the Netherlands and their interest in pharmacogenetic research ANA Daud, EL Bergsma, JEH Bergman, HEK De Walle, ... BMC Pregnancy and Childbirth 17, 1-9, 2017	15	2017
Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study ANA Daud, JEH Bergman, WS Kerstjens-Frederikse, P van der Vlies, ... Pharmacogenomics 18 (10), 987-1001, 2017	8	2017
Serotonin reuptake inhibitors (SRIs) and the risk of fetal congenital heart anomalies (CHA): An exploratory pharmacogenetics study AN Daud, W Frederikse, JEH Bergman, P van der Vlies, E Hak, R Berger, ... Naunyn-Schmiedebergs Archives of Pharmacology 390 (Suppl. 1), S24-100, 2017		2017
Supplementary Materials: The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors—Is Pharmacogenetics the Key? ANA Daud, JEH Bergman, WS Kerstjens-Frederikse, H Groen, B Wilffert Int. J. Mol. Sci 17, 1333, 2016		2016
The effect of P-glycoprotein-mediated drug interactions in pregnancy on the risk of congenital anomalies ANA Daud, JEH Bergman, MK Bakker, H Wang, WS Kerstjens-Frederikse, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 24, 30-31, 2015		2015
Research Report 1: Drug Interaction in Pregnancy: The Role of Placental Transporter Proteins in Fetal Drug Exposure MP Oktora, B Wilffert, ANA Daud Faculty of Science and Engineering, 2015		2015
Patient-reported side effects of lamotrigine during routine clinic visits NA Daud, AF Ab-Rahman Neurosciences Journal 17 (3), 269-270, 2012		2012
Metformin in gestational diabetes (MeGDia): A multicenter study on the knowledge, attitude and practice among Malaysian health care professionals ANA Daud, SN Harun, SMS Ghadzi, OY Ping, F Yusof, F Yusoff

The system can't perform the operation now. Try again later.

Articles 1–12